Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
CISCA Variant #02 | — | R 678 | 21d | — | — | — | — | — |
Tamoxifen monotherapy Variant #06 | — | R 410 | 28d | ~7.2 mo | — | ~8 | ~R 3 279 PFS proxy · indirect | 1 |
Altretamine and Cisplatin (HD) Variant #01 Partial | — | R 188 | 21d | — | — | — | — | — |
CAP (Platinol) Partial | — | — | — | — | — | — | — | — |
4 of 4 regimens shown